Among patients with advanced non-small
cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in survival without progression of the cancer, but not with overall survival, according to a study in the April 9 issue of JAMA.
Not exact matches
Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker - guided treatment is cost - effective compared with standard chemotherapy treatment
without any molecular testing in the metastatic non-small
cell lung cancer (NSCLC) setting in the United States.
A Phase III Randomized Trial of Adjuvant Chemotherapy with or
without Bevacizumab for Patients with Completely Resected Stage IB (> or = 4 cm)- IIIA Non-Small
Cell Lung Cancer (NSCLC)
One study presented in the journal — from a group led by Patrick Singleton, PhD, assistant professor of medicine at the University of Chicago Medicine — shows how opioids already present in the body can enhance the malignant tendencies of human
lung cancer cells transplanted into mice, even
without the addition of morphine.
Because of this, small
cell lung cancer is treated with chemotherapy, with or
without additional radiotherapy.